search
Back to results

Permeaderm Versus Homograft for Full-thickness Burns

Primary Purpose

Full Thickness Burn

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PermeaDerm for temporary coverage
FHCA for temporary coverage
PermeaDerm over autograft
FHCA over autograft
Sponsored by
The University of Texas Medical Branch, Galveston
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Full Thickness Burn focused on measuring PermeaDerm, Cadaver skin, full thickness burn, temporary coverage

Eligibility Criteria

6 Months - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • ≥ 2 % total body surface area (TBSA) full thickness burned.
  • Patients with two adjacent or body symmetrical full thickness burned areas (each ≥ 1 TBSA) and comparable in size (TBSA ± 0.5), that require debridement and autografting.

Exclusion Criteria:

  • Time from injury to admission >= 5 days
  • Sepsis on admission or clinically suspected infection (as per attending physician)
  • Pregnancy or childbearing
  • Positive HIV or hepatitis screens
  • History of active malignancy
  • Patients who do not require surgical debridement and autografting
  • Patient with burn injuries originating from other causes (chemical, and frostbite)

Sites / Locations

  • University of texas Medical Branch Galveston

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Experimental

Active Comparator

Arm Label

Permeaderm as temporary coverage

FHCA as temporary coverage

Permeaderm over widely meshed autograft

FHCA over widely meshed autograft

Arm Description

A: temporary coverage with PermeaDerm until autografting: After randomization of study site, study dressing will be applied as temporary coverage on freshly excised full-thickness burn wounds.

B: temporary coverage with FHCA until autografting: After randomization of study site, study dressing will be applied as temporary coverage on freshly excised full-thickness burn wounds.

C: temporary coverage of widely meshed autograft with PermeaDerm until healing occurs and PermeaDerm can remove

D: temporary coverage of widely meshed autograft with FHCA until healing occurs

Outcomes

Primary Outcome Measures

Time to heal
Time until study areas are 95% healed, as rated by blinded assessors based on photographs

Secondary Outcome Measures

Incidence of adherence problems (Arm 2)
% of non-adherence at first dressing change
Incidence of adherence problems (Arm 1)
% of non-adherence at first dressing change and at time of dressing removal before grafting
Incidence of infections
Incidence of infection, defined as >10x5 bacteria/g tissue, Only taken when infection suspected.
Rate of fluid/hematoma accumulation
% of fluid accumulation/hematoma formation at first dressing change
Cost effectiveness
Price per cm square of each study dressing
Scar assessment with Patient and Observer Assessment Scale (POSAS)
Using Patient and Observer Scar Assessment Scale POSAS, what is a composite score that is rating the overall appearance of the scar, based on each single score for rating vascularity, pigmentation, thickness, relief, pliability, surface. Every subscore ranges from 1-10. The composite score is calculated as an average of the subscores. Higher numbers mean worse scarring.
Scar assessment with Patient and Observer Assessment Scale (POSAS)
Using Patient and Observer Scar Assessment Scale POSAS, what is a composite score that is rating the overall appearance of the scar, based on each single score for rating vascularity, pigmentation, thickness, relief, pliability, surface. Every subscore ranges from 1-10. The composite score is calculated as an average of the subscores. Higher numbers mean worse scarring.
Scar assessment with Patient and Observer Assessment Scale (POSAS)
Using Patient and Observer Scar Assessment Scale POSAS, what is a composite score that is rating the overall appearance of the scar, based on each single score for rating vascularity, pigmentation, thickness, relief, pliability, surface. Every subscore ranges from 1-10. The composite score is calculated as an average of the subscores. Higher numbers mean worse scarring.
Scarring with DermaLab Combo device: Viscoelasticity
Measured through negative suction and retraction time.
Scarring with DermaLab Combo device: Viscoelasticity
Measured through negative suction and retraction time.
Scarring with DermaLab Combo device: Viscoelasticity
Measured through negative suction and retraction time.
Scarring with DermaLab Combo device: Hydration
Measured based on skin conductance.
Scarring with DermaLab Combo device: Hydration
Measured based on skin conductance.
Scarring with DermaLab Combo device: Hydration
Measured based on skin conductance.
Scarring with DermaLab Combo device: Pigmentation
Measured based on light absorption of melanin and erythema
Scarring with DermaLab Combo device: Pigmentation
Measured based on light absorption of melanin and erythema
Scarring with DermaLab Combo device: Pigmentation
Measured based on light absorption of melanin and erythema
Scarring with DermaLab Combo device: Trans epithermal water loss
Measuring evaporation in g/meter square/hour
Scarring with DermaLab Combo device: Trans epithermal water loss
Measuring evaporation in g/meter square/hour
Scarring with DermaLab Combo device: Trans epithermal water loss
Measuring evaporation in g/meter square/hour

Full Information

First Posted
December 11, 2020
Last Updated
December 11, 2020
Sponsor
The University of Texas Medical Branch, Galveston
Collaborators
Shriners Hospitals for Children
search

1. Study Identification

Unique Protocol Identification Number
NCT04673435
Brief Title
Permeaderm Versus Homograft for Full-thickness Burns
Official Title
Biosynthetic Skin Substitute Versus Frozen Human Cadaver Allograft for Temporary Coverage of Excised Full-thickness Burn Wounds
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Withdrawn
Why Stopped
Protocol was withdrawn and closed by IRB in April, 2018 prior to enrollment of first patient
Study Start Date
January 31, 2018 (Anticipated)
Primary Completion Date
July 31, 2019 (Anticipated)
Study Completion Date
July 31, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The University of Texas Medical Branch, Galveston
Collaborators
Shriners Hospitals for Children

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Frozen Human Cadaver Allograft (FHCA) is, nowadays, the gold standard for temporary coverage of excised full-thickness burns, but is also very expensive and requires additional personnel and major storage spaces in comparison to other products. The purpose of this study is to determine the extent to which PermeaDerm® dressing promotes wound bed maturation when used as a temporary dressing for excised full-thickness burn wounds. Efficacy and safety in promoting wound bed maturation for successive autografting will be determined through direct comparison to FHCA.
Detailed Description
In this prospective, randomized, matched design pilot study, we aim to compare the current standard of care FHCA to PermeaDerm®. 30 patients for each study arm (n total = 60) meeting the inclusion criteria will be enrolled to randomly receive FHCA and PermeaDerm® on two adjacent or symmetric body areas. Prior to randomization of study areas and application of study dressings, baseline assessments of wound size and burn depth will be performed by the experienced physician and documented using photography and when indicated laser Doppler (Moor Laser Speckle®, Moor Instruments, Devon, UK) measurements. Percentage of graft take and wound healing after removal of the temporary wound dressings and secondary autografting (study arm 1) or after excision and direct autografting with wiedely-meshed autograft and temporary wound dressings as overlay (study arm 2) will be assessed. Secondary outcomes will include complications such as infections, signs of rejection/non-adherence, fluid accumulation/hematoma beneath dressings and mid- and long-term clinical scar maturation, as assessed by the POSAS and objectively with the DermaLab Combo® device (Cortex Technology ApS, Hadsund, Denmark).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Full Thickness Burn
Keywords
PermeaDerm, Cadaver skin, full thickness burn, temporary coverage

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Randomized matched design with application of both study dressings symmetrical or adjacent body sites at the same time.
Masking
Outcomes Assessor
Masking Description
Outcomes assessors (healing time and scar assessments) are blinded.
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Permeaderm as temporary coverage
Arm Type
Experimental
Arm Description
A: temporary coverage with PermeaDerm until autografting: After randomization of study site, study dressing will be applied as temporary coverage on freshly excised full-thickness burn wounds.
Arm Title
FHCA as temporary coverage
Arm Type
Active Comparator
Arm Description
B: temporary coverage with FHCA until autografting: After randomization of study site, study dressing will be applied as temporary coverage on freshly excised full-thickness burn wounds.
Arm Title
Permeaderm over widely meshed autograft
Arm Type
Experimental
Arm Description
C: temporary coverage of widely meshed autograft with PermeaDerm until healing occurs and PermeaDerm can remove
Arm Title
FHCA over widely meshed autograft
Arm Type
Active Comparator
Arm Description
D: temporary coverage of widely meshed autograft with FHCA until healing occurs
Intervention Type
Device
Intervention Name(s)
PermeaDerm for temporary coverage
Intervention Description
See above
Intervention Type
Device
Intervention Name(s)
FHCA for temporary coverage
Intervention Description
See above
Intervention Type
Device
Intervention Name(s)
PermeaDerm over autograft
Intervention Description
See above
Intervention Type
Device
Intervention Name(s)
FHCA over autograft
Intervention Description
see above
Primary Outcome Measure Information:
Title
Time to heal
Description
Time until study areas are 95% healed, as rated by blinded assessors based on photographs
Time Frame
up to 8 weeks after initial grafting
Secondary Outcome Measure Information:
Title
Incidence of adherence problems (Arm 2)
Description
% of non-adherence at first dressing change
Time Frame
up to 21 days after initial surgery
Title
Incidence of adherence problems (Arm 1)
Description
% of non-adherence at first dressing change and at time of dressing removal before grafting
Time Frame
up to 21 days after initial surgery
Title
Incidence of infections
Description
Incidence of infection, defined as >10x5 bacteria/g tissue, Only taken when infection suspected.
Time Frame
up to 8 weeks after initial grafting
Title
Rate of fluid/hematoma accumulation
Description
% of fluid accumulation/hematoma formation at first dressing change
Time Frame
up to 21 days after initial surgery
Title
Cost effectiveness
Description
Price per cm square of each study dressing
Time Frame
Until grafting of study sites, within 21 days
Title
Scar assessment with Patient and Observer Assessment Scale (POSAS)
Description
Using Patient and Observer Scar Assessment Scale POSAS, what is a composite score that is rating the overall appearance of the scar, based on each single score for rating vascularity, pigmentation, thickness, relief, pliability, surface. Every subscore ranges from 1-10. The composite score is calculated as an average of the subscores. Higher numbers mean worse scarring.
Time Frame
Assessed within 4 weeks after 95% wound healing
Title
Scar assessment with Patient and Observer Assessment Scale (POSAS)
Description
Using Patient and Observer Scar Assessment Scale POSAS, what is a composite score that is rating the overall appearance of the scar, based on each single score for rating vascularity, pigmentation, thickness, relief, pliability, surface. Every subscore ranges from 1-10. The composite score is calculated as an average of the subscores. Higher numbers mean worse scarring.
Time Frame
Assessed between 3 and 9 months after initial admission
Title
Scar assessment with Patient and Observer Assessment Scale (POSAS)
Description
Using Patient and Observer Scar Assessment Scale POSAS, what is a composite score that is rating the overall appearance of the scar, based on each single score for rating vascularity, pigmentation, thickness, relief, pliability, surface. Every subscore ranges from 1-10. The composite score is calculated as an average of the subscores. Higher numbers mean worse scarring.
Time Frame
Assessed between 9-15 months after initial admission
Title
Scarring with DermaLab Combo device: Viscoelasticity
Description
Measured through negative suction and retraction time.
Time Frame
Assessed within 4 weeks after 95% wound healing
Title
Scarring with DermaLab Combo device: Viscoelasticity
Description
Measured through negative suction and retraction time.
Time Frame
Assessed between 3 and 9 months after initial admission
Title
Scarring with DermaLab Combo device: Viscoelasticity
Description
Measured through negative suction and retraction time.
Time Frame
Assessed between 9-15 months after initial admission
Title
Scarring with DermaLab Combo device: Hydration
Description
Measured based on skin conductance.
Time Frame
Assessed within 4 weeks after 95% wound healing
Title
Scarring with DermaLab Combo device: Hydration
Description
Measured based on skin conductance.
Time Frame
Assessed between 3 and 9 months after initial admission
Title
Scarring with DermaLab Combo device: Hydration
Description
Measured based on skin conductance.
Time Frame
Assessed between 9-15 months after initial admission
Title
Scarring with DermaLab Combo device: Pigmentation
Description
Measured based on light absorption of melanin and erythema
Time Frame
Assessed within 4 weeks after 95% wound healing
Title
Scarring with DermaLab Combo device: Pigmentation
Description
Measured based on light absorption of melanin and erythema
Time Frame
Assessed between 3 and 9 months after initial admission
Title
Scarring with DermaLab Combo device: Pigmentation
Description
Measured based on light absorption of melanin and erythema
Time Frame
Assessed between 9-15 months after initial admission
Title
Scarring with DermaLab Combo device: Trans epithermal water loss
Description
Measuring evaporation in g/meter square/hour
Time Frame
Assessed within 4 weeks after 95% wound healing
Title
Scarring with DermaLab Combo device: Trans epithermal water loss
Description
Measuring evaporation in g/meter square/hour
Time Frame
Assessed between 3 and 9 months after initial admission
Title
Scarring with DermaLab Combo device: Trans epithermal water loss
Description
Measuring evaporation in g/meter square/hour
Time Frame
Assessed between 9-15 months after initial admission

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ≥ 2 % total body surface area (TBSA) full thickness burned. Patients with two adjacent or body symmetrical full thickness burned areas (each ≥ 1 TBSA) and comparable in size (TBSA ± 0.5), that require debridement and autografting. Exclusion Criteria: Time from injury to admission >= 5 days Sepsis on admission or clinically suspected infection (as per attending physician) Pregnancy or childbearing Positive HIV or hepatitis screens History of active malignancy Patients who do not require surgical debridement and autografting Patient with burn injuries originating from other causes (chemical, and frostbite)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David N Herndon, MD
Organizational Affiliation
The University of Texas Medical Branch, Galveston
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of texas Medical Branch Galveston
City
Galveston
State/Province
Texas
ZIP/Postal Code
77555
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
data won't be shared

Learn more about this trial

Permeaderm Versus Homograft for Full-thickness Burns

We'll reach out to this number within 24 hrs